Journal article
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Abstract
Oncolytic viruses are under development for tumor treatment. David Kirn and colleagues now report their results of a randomized phase 2 dose-finding trial of JX-594, an oncolytic immunotherapeutic vaccinia virus, in patients with advanced hepatocellular carcinoma. The study shows that high-dose JX-594 was associated with significantly improved overall survival and induced radiographic responses and antitumor immunity.
Authors
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW
Journal
Nature Medicine, Vol. 19, No. 3, pp. 329–336
Publisher
Springer Nature
Publication Date
March 2013
DOI
10.1038/nm.3089
ISSN
1078-8956